Hematologic Malignancy
EBV-Related Hodgkin Lymphoma
CI-CAN-00002571Explore in graph →
Hematologic1 active trials
- NCIt
- C27692
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00002571Explore in graph →
Clinical trials
5 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04664179 | EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma(CILESTE) | recruiting | Phase 1 | 52 | Baylor College of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas(NAVAL-1) | terminated | Phase 2 | 102 | Viracta Therapeutics, Inc.INDUSTRY | 14 | Jul 28, 2025 |
| clinicaltrials |
| NCT03546101 | Early Detection of Epstein-Barr Virus Related Disease. | completed | — | 1,527 | University of AarhusOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT02973113 | Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)(PREVALE) | completed | Phase 1 | 8 | Baylor College of MedicineOTHER | 1 | Jul 21, 2021 | clinicaltrials |
| NCT00058617 | Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGEL | completed | Phase 1 | 13 | Baylor College of MedicineOTHER | 1 | Feb 15, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jun 25, 2026source: clinicaltrials